Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : N::A symbols : Cybn save search
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -1.96%
H: 0.0%
C: -4.65%
conference
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Published: 2024-03-18 (Crawled : 17:00) - biospace.com/
MDBH | $8.11 -10.73% -12.02% 9.7K
|
|
| O: -1.69%
H: 7.09%
C: 5.26%
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.0%
H: 0.22%
C: -2.17%
day
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 1.59%
H: 7.78%
C: 5.55%
cyb004 study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
Published: 2024-03-12 (Crawled : 11:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -5.59%
H: 18.53%
C: 16.8%
meeting order therapeutics agreement
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
Published: 2024-02-14 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -1.31%
H: 0.0%
C: -2.17%
business financial results
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 1.42%
H: 0.0%
C: -10.34%
japan grant program
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -0.61%
H: 2.83%
C: 2.83%
therapeutics
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.0%
H: 2.37%
C: 0.34%
cyb004 fda clearance study
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
first fibromyalgia treatment trial therapeutics
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
Published: 2024-01-04 (Crawled : 13:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.65%
H: 3.49%
C: 3.49%
topline results
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
Published: 2023-12-06 (Crawled : 13:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -2.65%
H: 2.36%
C: 1.65%
cyb003 patent grant program psilocybin
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
Published: 2023-12-05 (Crawled : 15:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -1.63%
H: 0.45%
C: -1.25%
cyb003 topline meeting results
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 2.3%
H: 0.0%
C: -8.14%
cyb003 positive topline study
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
Published: 2023-11-20 (Crawled : 13:30) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 2.04%
H: 0.17%
C: -1.68%
cyb003 review depression city topline study
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
Published: 2023-11-15 (Crawled : 14:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.22%
H: 1.74%
C: -1.3%
presentation meeting
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
Published: 2023-11-15 (Crawled : 08:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 0.22%
H: 1.74%
C: -1.3%
business financial results
Cybin Announces up to US$64 Million Offering of Units
Published: 2023-11-10 (Crawled : 14:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: -12.45%
H: 3.95%
C: -3.28%
offering
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
Published: 2023-10-31 (Crawled : 23:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 11.35%
H: 9.32%
C: -4.16%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
AXSM | $68.26 -1.29% -1.3% 430K
|
Health Technology
|
| O: 0.0%
H: 3.76%
C: 3.75%
cyb003 rapid positive depression meeting
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -2.24% 2.8M
|
n/a
|
| O: 5.03%
H: 8.95%
C: 7.22%
patent grant
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.